Journal of the European Academy of Dermatology and Venereology

Papers
(The H4-Index of Journal of the European Academy of Dermatology and Venereology is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Issue Information325
Announcement211
Editor's Picks January 2024208
Announcement176
Commentary on vitiligo patient population and disease burden in France: VIOLIN Study results from the CONSTANCES cohort163
146
Pioneers in Dermatology and Venereology: an interview with Professor Sarolta Kárpáti120
Pioneers in Dermatology and Venereology: an Interview with Professor David M. Pariser99
Pioneers in Dermatology and Venereology: An Interview with Professor An Goossens98
Clinical evaluation of anaesthetic‐like effect of two dermocosmetic formulations containing Aquaphilus dolomiae extract‐G3 in subjects with sensitive facial skin97
Announcement85
Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 202485
2013–2023: A decade of progress and challenges in dermatology as reflected in JEADV83
Assessing the efficacy of selective JAK inhibitors for alopecia areata with a patient‐centered approach80
Application of integrated skincare in medical aesthetics: A literature review75
Microinfusion of 5‐fluorouracil using a tattooing machine in keloid treatment73
Comparison of performance of SCORTEN, ABCD‐10 and Re‐SCORTEN in a cohort of patients with Stevens–Johnson syndrome/toxic epidermal necrolysis65
Course and outcome of chilblain‐like acral lesions during COVID‐19 pandemic64
Clinical and molecular diagnosis of genodermatoses: Review and perspectives63
High prevalence of extracutaneous involvement in ITG junctional epidermolysis bullosa62
Two cases of cerebrovascular accidents following the induction dose of risankizumab59
Disproportionate quality of life decline and unaddressed limitations in amlitelimab atopic dermatitis trial54
Risk analysis of systemic side effects of tumescent local anaesthesia in the surgical treatment of geriatric and multimorbid patients with skin cancer52
Hidradenitis suppurativa: One step forward in timely diagnosis and appropriate treatment52
Are non‐fungible tokens the barrier to realizing the Dermoverse?51
Patient presentation, skin biopsy utilization and cutaneous malignant melanoma incidence and mortality in northern Italy: Trends and correlations51
Can we trust AI for acne advice: A double‐blind performance comparison with NICE guidelines50
Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice50
Paradoxical joint and muscle pain in a patient treated with anifrolumab and belimumab50
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma50
Reply to comments by Tadulewicz and Muklewicz on socio‐economic outcomes of atopic dermatitis50
Update on cutaneous lupus erythematosus pathogenesis, diagnosis and management47
Advances in biologic therapy of psoriasis47
Comparison of molecular and serological assays on cerebrospinal fluid for the diagnosis of neurosyphilis47
Louis Adolphus Duhring: An enduring legacy47
New onset of systemic lupus erythematosus following COVID‐19 mRNA vaccination46
Intriguing concept of pigmented contact dermatitis: Further understanding the role of hair colours including natural henna46
Aquagenic pruritus: A web‐based survey study exploring itch characteristics, therapeutic options and patient perspectives46
Scar diastasis index: a smart and reproducible tool to evaluate long‐standing scars45
Hand–foot syndrome like eruption following mRNA COVID‐19 vaccine44
Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event 44
A new era for alopecia areata: New treatments and improved knowledge of the condition44
43
Impact of menopause on the skin…information still insufficient43
Comment on ‘Negative SARS‐CoV‐2 antibodies in patients with positive immunohistochemistry for spike protein in pityriasis rosea‐like eruptions’43
0.13642001152039